Servier acquires lymphoma drug Pixuvri from CTI BioPharma

This article was originally published here

Pixuvri has approval for the treatment of adult patients having multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphoma, a type of blood cancer. The drug is a cytotoxic

The post Servier acquires lymphoma drug Pixuvri from CTI BioPharma appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply